Updated:
ARKRAY&PARTNERS
Tadashi Ogasawara's Singapore-based family office invests capital from the ARKRAY medical device fortune across global venture and real assets.
ARKRAY&PARTNERS
Tadashi Ogasawara established ARKRAY&PARTNERS in Singapore after building ARKRAY Inc. into a global provider of clinical diagnostics equipment, including blood glucose monitoring systems and urinalysis devices. The parent company, headquartered in Kyoto, operates in over 80 countries and generates the foundational wealth for the family office. The family office invests across venture capital, private equity, and real estate. Its venture activity skews toward enterprise software and healthtech — an adjacency to the Ogasawara family's industrial roots — while real estate commitments include Singapore commercial properties and Japanese multifamily assets. The firm participates in direct deals and co-investments alongside other Asian family offices, though specific portfolio companies remain privately held. ARKRAY&PARTNERS runs a lean operation typical of Asia-Pacific single family offices, with investment professionals based in Singapore. No separate philanthropic foundation is publicly identified, though the Ogasawara family has historically supported healthcare access initiatives in Southeast Asia through corporate channels. What distinguishes ARKRAY&PARTNERS from other Asian family offices is its deliberate separation from the parent operating company, ARKRAY Inc. The family office runs an independent investment mandate from Singapore rather than functioning as a corporate venture arm — a structure that gives its deal teams latitude to invest outside medtech and diagnostics, while still benefiting from the industrial networks the Ogasawara name commands in Japan's Kansai region.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Singapore
City
Singapore
Corporate office
Sunnyvale, Singapore
Principals
Tadashi Ogasawara
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at ARKRAY&PARTNERS?
Investment decisions trace to Tadashi Ogasawara, the founder of ARKRAY Inc. and principal of the family office. The firm has not publicly disclosed a separate CIO or investment committee structure, which is consistent with the single-principal governance model common among first-generation Asian family offices. Day-to-day execution is managed by a Singapore-based team.
How is ARKRAY&PARTNERS related to ARKRAY Inc.?
ARKRAY&PARTNERS is a separate legal entity from ARKRAY Inc., the Kyoto-headquartered medical device manufacturer. The family office manages the Ogasawara family's private wealth generated from the operating company, but it is not a corporate venture arm. This separation allows the investment team to pursue opportunities outside the diagnostics and medtech sectors.
Does ARKRAY&PARTNERS invest only in healthcare?
No. While the family's wealth originates from medical device manufacturing, ARKRAY&PARTNERS diversifies across enterprise software, venture capital, and real estate. The firm's Singapore base and independent mandate allow commitments outside healthcare, though healthtech remains a natural adjacency given the family's industrial expertise.
What investment stages does ARKRAY&PARTNERS target?
The firm participates across venture and growth equity stages, primarily through direct investments and co-investment arrangements with Asian family office networks. Real estate commitments tend toward stabilized assets in Singapore and Japan. Specific fund commitments or limited partner relationships have not been publicly disclosed.
Where does the underlying wealth come from?
The Ogasawara family fortune derives from ARKRAY Inc., which Tadashi Ogasawara founded in Kyoto. The company manufactures clinical diagnostic test systems — including blood glucose meters sold under the Glucocard brand — and distributes to healthcare systems across more than 80 countries. The family office was subsequently established in Singapore to manage the resulting liquidity.
Does ARKRAY&PARTNERS co-invest alongside external GPs?
Yes, the family office has a known posture of participating in co-investment syndicates alongside other Asian family offices and, less frequently, institutional GPs. These co-investment relationships are managed on a deal-by-deal basis rather than through a formalized club structure, and the firm does not publicly disclose its co-investment partners.
Why is ARKRAY&PARTNERS based in Singapore rather than Japan?
Singapore's regulatory environment and tax treaty network provide significant advantages for managing cross-border family wealth, which is a common rationale for Asian families establishing offices there. For the Ogasawara family, a Singapore domicile also creates operational distance from the Kyoto-based parent company, reinforcing the family office's independence from ARKRAY Inc.'s corporate priorities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: